Oppenheimer & CO Inc Avadel Pharmaceuticals PLC Transaction History

Oppenheimer & CO Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	SELL	$12.55 - $17.22 $10,240 - $14,051	-816 Reduced 2.15%	37,095 $626,000
Q4 2023 Feb 13, 2024	SELL	$9.64 - $14.59 $19,280 - $29,180	-2,000 Reduced 5.01%	37,911 $535,000
Q3 2023 Nov 07, 2023	BUY	$10.3 - $15.99 $58,328 - $90,551	5,663 Added 16.54%	39,911 $411,000
Q2 2023 Aug 02, 2023	BUY	$8.48 - $16.48 $92,347 - $179,467	10,890 Added 46.62%	34,248 $564,000
Q1 2023 May 10, 2023	BUY	$6.41 - $9.95 $149,724 - $232,412	23,358 New	23,358 $213,000
Q4 2020 Feb 11, 2021	SELL	$5.03 - $7.95 $140,357 - $221,836	-27,904 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$5.02 - $8.98 $25,551 - $45,708	5,090 Added 22.31%	27,904 $141,000
Q2 2020 Aug 11, 2020	BUY	$7.25 - $11.75 $165,401 - $268,064	22,814 New	22,814 $184,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.